Skip to main content
. 2016 May 15;7(22):31652–31662. doi: 10.18632/oncotarget.9386

Figure 6. CXCL16 deficiency suppresses gene expression of proinflammatory molecules in the kidney after cisplatin treatment.

Figure 6

A. Quantitative analysis of TNF-α mRNA expression in kidneys of WT and CXCL16 KO mice after cisplatin or saline treatment. *P < 0.05 vs. WT CON; #P < 0.05 vs. CXCL16 KO cisplatin; +P < 0.05 vs. WT cisplatin. n = 6 in each group. B. Quantitative analysis of IL-6 mRNA expression in kidneys of WT and CXCL16 KO mice after cisplatin or saline treatment. *P < 0.05 vs. WT saline; ##P < 0.01 vs. CXCL16 KO cisplatin; +P < 0.05 vs. WT cisplatin. n = 6 in each group. C. Quantitative analysis of TGF-β1 mRNA expression in kidneys of WT and CXCL16-KO mice after cisplatin or saline treatment. **P < 0.01 vs. WT saline; ##P < 0.01 vs. CXCL16 KO cisplatin; +P < 0.05 vs. WT cisplatin. n = 6 in each group. D. Quantitative analysis of IL-1β mRNA expression in kidneys of WT and CXCL16 KO mice after cisplatin or saline treatment. **P < 0.01 vs. WT saline; #P < 0.05 vs. CXCL16 KO cisplatin; ++P < 0.01 vs. WT cisplatin. n = 6 in each group. GAPDH, glyceraldehyde-3-phosphate dehydrogenase.